These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28699779)

  • 1. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative Contracting for Pharmaceuticals and Medicaid's Best-Price Rule.
    Sachs R; Bagley N; Lakdawalla DN
    J Health Polit Policy Law; 2018 Feb; 43(1):5-18. PubMed ID: 28972020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
    J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AWP reimbursement scrutinized by several states.
    Carroll J
    Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
    [No Abstract]   [Full Text] [Related]  

  • 8. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare and drug pricing.
    Iglehart JK
    N Engl J Med; 2003 Apr; 348(16):1590-7. PubMed ID: 12700381
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
    Academy of Managed Care Pharmacy
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of single exit pricing (SEP) on medicine product withdrawal from the private healthcare market in South Africa.
    Naidoo K; Suleman F
    S Afr Med J; 2021 Apr; 111(5):444-447. PubMed ID: 34852886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy: evidence, value and affordability in the US health care system.
    Hampson G; Towse A; Pearson SD; Dreitlein WB; Henshall C
    J Comp Eff Res; 2018 Jan; 7(1):15-28. PubMed ID: 29144165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
    Gandjour A; Gafni A; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.